1-3 of 3
Susan Snodgrass, MD
Close
Sort by
Journal Articles

Transcend NHL 001: Immunotherapy with the CD19-Directed CAR T-Cell Product JCAR017 Results in High Complete Response Rates in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Jeremy S. Abramson, MD, Lia Palomba, MD, Leo I Gordon, MD, Matthew Lunning, DO, Jon Arnason, MD, Andres Forero-Torres, MD, Tina M. Albertson, MD PhD, Victoria Shaw Exton, Claire Sutherland, PhD, Benhuai Xie, PhD, Susan Snodgrass, MD, Tanya Siddiqi, MD
Journal: Blood
Blood (2016) 128 (22): 4192.
https://doi.org/10.1182/blood.V128.22.4192.4192
Published: 2016
Journal Articles

Phase II Study of the Pan-Deacetylase Inhibitor Panobinostat in Combination with Bortezomib and Dexamethasone in Relapsed and Bortezomib-Refractory Multiple Myeloma (PANORAMA 2)

Paul G. Richardson, MD, Melissa Alsina, MD, Donna M. Weber, MD, Steven E. Coutre, MD, Sagar Lonial, MD, Cristina Gasparetto, MD, Ghulam Warsi, PhD, Michael Ondovik, PharmD, MBA, Sutapa Mukhopadhyay, PhD, Susan Snodgrass, MD, Robert Schlossman, MD
Journal: Blood
Blood (2011) 118 (21): 814.
https://doi.org/10.1182/blood.V118.21.814.814
Published: 2011
Journal Articles

Costs, Persistence, and Hospitalizations Associated with the Use of Iron-Chelating Therapies in Sickle Cell Disease in Medicaid Patients

Edward P Armstrong, Pharm.D, Grant H Skrepnek, PhD, Samir K. Ballas, MD, Peter Kwok, Pharm.D, Susan Snodgrass, MD, Medha Sasane, PhD
Journal: Blood
Blood (2011) 118 (21): 3152.
https://doi.org/10.1182/blood.V118.21.3152.3152
Published: 2011